Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04978064
Other study ID # eIPV
Secondary ID 2021671331162021
Status Completed
Phase N/A
First received
Last updated
Start date October 7, 2021
Est. completion date November 14, 2022

Study information

Verified date January 2023
Source Universidad de Granada
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will assess the need and feasibility of randomising a sufficiently large number of women exposed to IPV during pregnancy in a full-scale future randomised trial. To achieve this, the investigators will: 1. estimate rates of consent to randomization, and the rates of adherence and dropout following randomization (for the use in sample size estimation) 2. determine recruitment duration 3. examine the women's perception about the benefit of the intervention 4. determine the reasons for acceptability, non-adherence, and obstacles to recruitment, randomisation and consent through qualitative interviews


Description:

Introduction. Intimate partner violence (IPV) during pregnancy, a condition as common as obstetrics conditions like gestational diabetes, is associated with maternal and neonatal complications. Systematic detection of IPV is not well established in antenatal screening probably because the effectiveness of protective interventions has not been evaluated. Among mothers exposed to IPV, e-health interventions during pregnancy may be beneficial. Prior to performing a full-scale effectiveness trial for such an intervention, a pilot study is required to assess the need and feasibility of randomising a sufficiently large number of women at exposed to IPV during pregnancy. Methods. The eIPV trial is a randomised pilot study nested within a cohort of consenting mothers at <12 weeks' gestation who screen positive for IPV in the first antenatal visit and accept an e-health package (psychological counselling by videoconference) in Spain and Denmark. Twenty eligible mothers from the above cohort will be randomised to either intervention or control. The intervention group will receive the e-health package as part of the cohort. The control group will be invited to accept a delay in the intervention (e-health package eight weeks later). After consenting to delay, the control group will provide comparative data without losing the opportunity of obtaining the intervention. The investigators will determine estimates of rates of informed consent to randomization, and the rates of adherence and dropout following randomization. Qualitative interviews will be conducted to examine the women's perception about the benefit of the intervention, reasons for acceptability and non-adherence, and obstacles to recruitment, randomisation and consent. The results will inform the feasibility and variance of key clinical outcome measures for estimation of sample size of the full-scale effectiveness trial. Comment. The pilot study nested within the cohort study will allow us to obtain information about the rates of IPV in pregnancy, the acceptability of an e-health intervention and the availability of participants for randomisation into a large effectiveness trial.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date November 14, 2022
Est. primary completion date November 14, 2022
Accepts healthy volunteers No
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria: • Pregnant women at <12 weeks gestation, who screen positive in IPV at the first antenatal visit and accept the e-health package. Exclusion Criteria: - Women who cannot be informed about the study without their partners or other family members knowing - Women mentally or physically incapacity to participate in the study - Women below 16 years in Spain or below 18 years in Denmark - Inability to understand Danish/Spanish - Lack of internet and electronic device - Women with extreme severity of IPV. Women selected to participate in the trial in this situation will receive a danger assessment before randomisation and if the severity of IPV is confirmed, they will be routinely treated and supported according to the standard protocol in each country. Women who have same-sex partners will be screened, but their data will not be used for the purpose of this study.

Study Design


Intervention

Behavioral:
e-health psychological counselling
Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application "My Plan". The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model. Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study).

Locations

Country Name City State
Denmark Odense University Hospital Odense
Spain University of Granada Granada

Sponsors (3)

Lead Sponsor Collaborator
Universidad de Granada Odense University Hospital, University of Southern Denmark

Countries where clinical trial is conducted

Denmark,  Spain, 

References & Publications (3)

Martin-de-Las-Heras S, Velasco C, Luna-Del-Castillo JD, Khan KS. Breastfeeding avoidance following psychological intimate partner violence during pregnancy: a cohort study and multivariate analysis. BJOG. 2019 May;126(6):778-783. doi: 10.1111/1471-0528.15592. Epub 2019 Jan 24. — View Citation

Rasch V, Van TN, Nguyen HTT, Manongi R, Mushi D, Meyrowitsch DW, Gammeltoft T, Wu CS. Intimate partner violence (IPV): The validity of an IPV screening instrument utilized among pregnant women in Tanzania and Vietnam. PLoS One. 2018 Feb 1;13(2):e0190856. doi: 10.1371/journal.pone.0190856. eCollection 2018. — View Citation

Roman-Galvez RM, Martin-Pelaez S, Martinez-Galiano JM, Khan KS, Bueno-Cavanillas A. Prevalence of Intimate Partner Violence in Pregnancy: An Umbrella Review. Int J Environ Res Public Health. 2021 Jan 15;18(2):707. doi: 10.3390/ijerph18020707. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Consent rate for a future full-scale RCT trial Rate of women who were positive in IPV, consent to receive e-health package and consent to randomization in the control group. Three to nine months
Secondary Positivity rate of the cohort study (useful for planning the future full-scale randomised control trial): Rate of women who were positive in IPV and consent to receive e-health package Three to nine months
Secondary Completion rate in the intervention group a future full-scale RCT trial Rate of women who were recruited to intervention group, and for whom complete outcomes were obtained. Three to nine months
Secondary Completion rate in the control group a future full-scale RCT trial Rate of women who were recruited to control group, and for whom complete outcomes were obtained. Three to nine months
Secondary Recruitment duration for a future full-scale RCT trial Recruitment duration (in days) to get the pilot sample (5 women for the intervention group and 5 women for the control group, in each country) Three to nine months
Secondary Benefit of the intervention a future full-scale RCT trial Perception of the intervention by women participating in the pilot through the information obtained in qualitative interviews. Three to nine months
Secondary Perception about the delay of the intervention of the control group for a future full-scale RCT trial Perception about the duration of delay of the intervention of women in the control group (provided in the qualitative interviews). Three to nine months
Secondary Reasons for acceptability, non-adherence, and obstacles for a future full-scale RCT trial Reasons for acceptability, non-adherence, and obstacles to recruitment, randomization, consent and follow-up (provided in the qualitative interviews). Three to nine months
Secondary Follow up rate for a future full-scale RCT trial Rate of failure to obtain data in the follow-up. Three to nine months
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3